The advances in immunotherapy biomarkers of small cell lung cancer

doi:10.19401/j.cnki.1007-3639.2021.07.010

Abstract

Abstract: There is no obvious breakthrough in treatment for small cell lung cancer (SCLC) in more than 30 years, and the prognosis has not improved significantly. With the opening of the immune era, immune checkpoint inhibitors have made breakthroughs in SCLC treatment, but the overall benefit population is limited. How to select patients accurately and how to increase the efficacy of immunotherapy are hot topics in SCLC research. Therefore, this article summarized the current status of SCLC with focus on biomarkers related to SCLC immunotherapy, reviewed the progress in the research of immunotherapy markers in recent years, to provide clues and ideas for future immunotherapeutic strategies.

Key words: Small cell lung cancer, Immunotherapy, Biomarkers

XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia. The advances in immunotherapy biomarkers of small cell lung cancer[J]. China Oncology, 2021, 31(7): 635-639.

[1]	ZHU Yihui, LI Ting, HU Xichun. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(8): 754-761.
[2]	LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun . miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene [J]. China Oncology, 2021, 31(7): 581-588.
[3]	YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang . The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province [J]. China Oncology, 2021, 31(7): 616-628.
[4]	YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying . Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer [J]. China Oncology, 2021, 31(3): 203-211.
[5]	ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li . Advances in the treatment of BRAF V600-mutant non-small cell lung cancer [J]. China Oncology, 2021, 31(12): 1145-1152.
[6]	SHEN Yujia , FU Xiaolong . Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer [J]. China Oncology, 2021, 31(11): 1115-1125.
[7]	The Society of Gynecological Cancer of China Anti-Cancer Association, Chinese Society of Pathology of the Chinese Medical Association, National Pathology Quality Control Center. The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer (2021 edition) [J]. China Oncology, 2021, 31(11): 1126-1144.
[8]	LIU Qian , QIAO Meng , MAO Shiqi , YANG Shuo , LIU Yiwei , ZHAO Chao , LI Xuefei , REN Shengxiang , ZHOU Caicun . Impact of metastatic organ on prognosis in extensive-stage small cell lung cancer [J]. China Oncology, 2021, 31(1): 45-51.
[9]	HE Xi, JIAO Xiaodong, ZANG Yuansheng. Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer [J]. China Oncology, 2021, 31(1): 69-75.
[10]	LU Xiaoteng, XU Qing. A study on factors associated with recurrence of non-small cell lung cancer based on CT image features [J]. China Oncology, 2020, 30(8): 636-640.
[11]	ZHAO Haiyun, WU Xiaohua. Research progress of immunotherapy in ovarian cancer [J]. China Oncology, 2020, 30(7): 538-545.
[12]	ZHU Xiaodong, CHEN Siyuan. Combination therapy of immune checkpoint inhibitors: from rationale to practice [J]. China Oncology, 2020, 30(12): 969-976.
[13]	XU Wencai, GUO Leiming, CUI Yingying, LIU Xiao, JIANG Yue, GE Hong. The effect of lung stereotactic body radiotherapy on peripheral blood lymphocytes [J]. China Oncology, 2020, 30(12): 1013-1016.
[14]	ZHANG Longfu , YAO Jiamei , JIANG Dongxian , HOU Yingyong , ZHANG Xin . BIM combined with Scribble predicts treatment effect from chemotherapy in advanced non-small cell lung cancer [J]. China Oncology, 2020, 30(11): 865-871.
[15]	WANG Jie . Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer [J]. China Oncology, 2020, 30(10): 744-749.

The advances in immunotherapy biomarkers of small cell lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments